Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 6:11:1124.
doi: 10.3389/fphar.2020.01124. eCollection 2020.

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients

Pasquale Paolisso  1 , Luca Bergamaschi  1 , Emanuela Concetta D'Angelo  1 , Francesco Donati  1 , Maddalena Giannella  2 , Sara Tedeschi  2 , Renato Pascale  2 , Michele Bartoletti  2 , Giulia Tesini  2 , Mauro Biffi  1 , Benilde Cosmi  3 , Carmine Pizzi  1 , Pierluigi Viale  2 , Nazzareno Galié  1
Affiliations

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients

Pasquale Paolisso et al. Front Pharmacol. .

Abstract

Background: Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized patients.

Methods and results: Retrospective study of 450 laboratory-confirmed COVID-19 patients admitted to Sant'Orsola Bologna Hospital from March 01 to April 10, 2020. Clinical, laboratory and treatment data were collected and analyzed. The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared. Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40-60 mg twice daily) for 7 days. No significant differences in the main demographic characteristics and laboratory testings at admission were observed in the two heparin regimen subgroups, except for older age and prevalence of hypertension in the group treated with "standard" prophylaxis LMWH dosage. The intermediate LMWH administration was associated with a lower in-hospital all-cause mortality compared to the "standard" prophylactic LMWH dosage (18.8% vs. 5.8%, p = 0.02). This difference remained significant after adjustment with the propensity score for variables that differed significantly between the dosage groups (OR= 0.260, 95% CI 0.089-0.758, p=0.014).

Conclusions: Intermediate LMWH dosage seems to be associated with lower incidence of mortality compared to standard DVT prophylaxys in hospitalized COVID-19 patients. Our study paves the way to further pathophysiological investigations and controlled studies of anticoagulation therapy in Covid-19 disease.

Keywords: COVID- 19; DVT prophylaxis; LMWH (low molecular weight heparin); heparin; in-hospital mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart study.
See this image and copyright information in PMC

References

    1. Deshpande C. (2020). Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism? Ann. Intern. Med. M20-3255. 10.7326/M20-3255 - DOI - PMC - PubMed
    1. Driggin E., Madhavan M. V., Bikdeli B., Chuich T., Laracy J., Bondi-Zoccai G., et al. (2020). Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J. Am. Coll. Cardiol. 75, 2352–2371. 10.1016/j.jacc.2020.03.031 - DOI - PMC - PubMed
    1. Esko J. D., Lindahl U. (2001). Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169–173. 10.1172/JCI200113530 - DOI - PMC - PubMed
    1. Geleris J., Sun Y., Platt J., Zucker J., Baldwin M., Hripcsak G., et al. (2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl. J. Med. 382, 2411–2418. 10.1056/NEJMoa2012410 - DOI - PMC - PubMed
    1. Hernandez A. V., Roman Y. M., Pasupuleti V., Barboza J. J., White C. M. (2020). Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann. Intern. Med. 10.7326/M20-2496 - DOI - PubMed